The Food and Drug Administration has approved a vaccine for respiratory syncytial virus (RSV) for use in people ages 60 and older.
The U.S. Food and Drug Administration has approved the world's first-ever vaccine to prevent respiratory syncytial virus — a seasonal respiratory infection that can cause life-threatening pneumonia and dangerous inflammation of the lungs in high-risk groups — the agency announced Wednesday .
It's estimated that 60,000 to 160,000 older adults in the U.S. are hospitalized due to RSV each year, and 6,000 to 10,000 individuals in this age group die of the infection, according to the Centers for Disease Control and Prevention . RSV infection can also worsen existing medical conditions such as asthma, chronic obstructive pulmonary disease and congestive heart failure.
In a clinical trial , 12,500 older adults received the one-shot vaccine Arexvy and 12,500 received a placebo. Compared with the placebo group, the vaccinated group had an 82.6% lower chance of RSV-associated"lower respiratory tract disease," meaning an infection affecting the lungs, and a 94.1% lower chance of severe disease.
In another trial, where participants received only Arexvy, one vaccinated person developed Guillain-Barré syndrome, a rare condition where the immune system attacks nerves in the body, which can cause muscle weakness and sometimes paralysis. of developing this syndrome, but in these rare instances, the overall increase in risk has been very small.)
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
1st RSV vaccine for older adults in US cleared by FDA in historic approvalThe U.S. Food and Drug Administration has approved the first RSV vaccine in the U.S.
Read more »
In historic approval, FDA clears 1st RSV vaccine for older adults in USThe U.S. Food and Drug Administration has approved the first RSV vaccine in the U.S.
Read more »
1st vaccine for RSV approved by FDAThe U.S. has approved the first vaccine for RSV, shots to protect older adults.
Read more »
After decades of attempts, FDA approves 1st vaccine for RSVAfter decades of scientific research, the first vaccine for respiratory syncytial virus (RSV), designed to protect older adults, has been approved by the United States.
Read more »
US approves 1st vaccine for RSV after decades of attemptsAfter decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.
Read more »